A Phase 1b Open Label Positron Emission Tomography Study to Assess Changes in Abdominal [11C]AZ14132516 Uptake Following Administration of Single Doses of AZD7798 to Healthy Participants and Patients With Crohn's Disease
Latest Information Update: 25 Nov 2024
At a glance
- Drugs AZ 14132516 (Primary) ; AZD 7798 (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 21 Nov 2024 Status changed from active, no longer recruiting to completed.
- 26 Sep 2024 Planned End Date changed from 16 Sep 2024 to 11 Oct 2024.
- 26 Sep 2024 Planned primary completion date changed from 16 Sep 2024 to 11 Oct 2024.